Chromadex Total Liabilities

Chromadex (CDXC) currently reports a total liabilities of $26M as of September 2026. That compares with $27M in the prior-year period — down 6.7% year over year. Use the charts on this page to explore Chromadex's total liabilities history and peer comparisons.

Chromadex's total liabilities decreased from $27M to $26M — a 6.7% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromadex reported $26M in total liabilities as of September 2026. That compares with $27M in the prior-year period — down 6.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromadex, and consider following CDXC for alerts when major investors trade the stock.

Chromadex is classified in the Healthcare sector. On total liabilities, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDXC with unrelated industries.